Page last updated: 2024-08-21

vancomycin and oritavancin

vancomycin has been researched along with oritavancin in 89 studies

Research

Studies (89)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	14 (15.73)	18.2507
2000's	26 (29.21)	29.6817
2010's	44 (49.44)	24.3611
2020's	5 (5.62)	2.80

Authors

Authors	Studies
Judice, JK; Pace, JL	1
Arhin, FF; Belley, A; Draghi, DC; Grover, P; McKay, GA; Moeck, G; Parr, TR; Sahm, DF; Sarmiento, I	1
Belley, A; Beveridge, T; Harris, R; Moeck, G; Parr, T	1
Arhin, FF; Belley, A; Beveridge, T; Harris, R; McKay, G; Moeck, G; Neesham-Grenon, E; Parr, TR	1
Denis, O; Nguyen, HA; Struelens, MJ; Theunis, A; Tulkens, PM; Van Bambeke, F; Vergison, A	1
Arhin, FF; Beaulieu, S; McKay, GA; Moeck, G; Parr, TR; Sarmiento, I	1
Arhin, FF; Draghi, DC; Moeck, G; Parr, TR; Pillar, CM; Sahm, DF	1
Batta, G; Herczegh, P; Kéki, S; Komáromi, I; Mándi, A; Naesens, L; Ostorházi, E; Pintér, G; Röth, E; Rozgonyi, F; Sztaricskai, F; Takács-Novák, K	1
Arhin, FF; Ciblat, S; Dietrich, E; Far, AR; Métayer, C; Moeck, G; Parr, TR; Sarmiento, I; Tanaka, KS	1
Arhin, FF; Beaulieu, S; Belley, A; Fadhil, I; McKay, GA; Moeck, G; Parr, TR; Sarmiento, I	1
Chen, F; Gong, L; Guan, D; Huang, W; Lan, L; Li, J; Qiu, Y; Tang, F; Xiong, L; Zhang, N	1
Lonneman, M; Wetzel, C; Wu, C	1
Butler, TF; Cooper, RD; Huff, BE; Mullen, DL; Nicas, TI; Rodriguez, MJ; Snyder, NJ; Staszak, MA; Thompson, RC; Wilkie, SC; Zweifel, MJ	1
Furness, KM; Holloway, WJ; Johnson, JA; Johnson, RJ; McIntosh, AC; Qaiyumi, S; Schwalbe, RS; Steele-Moore, L	1
Houlihan, HH; Mercier, RC; Rybak, MJ	1
Hoban, DJ; Karlowsky, JA; Nicas, T; Zelenitsky, SA; Zhanel, GG	1
Beighton, D; Casewell, MW; Hill, RL; Kirk, M	1
Biavasco, F; Facinelli, B; Lupidi, R; Manso, E; Varaldo, PE; Vignaroli, C	1
Andrews, J; Fraise, AP; Wise, R	1
van den Bogaard, TE; van Tiel, FH	1
Elliott, TS; Harland, S; Tebbs, SE	1
Aeschlimann, JR; Houlihan, HH; Kaatz, GW; Mercier, RC; Rybak, MJ; Seo, SM	1
Baltch, AL; Bopp, LH; Ritz, WJ; Smith, RP	1
Carbon, C; Dautrey, S; Fantin, B; Le Guludec, D; Lefort, A; Petegnief, Y; Saleh-Mghir, A; Vallois, JM	1
Booker, B; Hoban, DJ; Karlowsky, JA; Laing, N; Zelenitsky, SA; Zhanel, GG	1
Aeschlimann, JR; Hershberger, E; Moldovan, T; Rybak, MJ	1
Ayem, ML; Léone, M; Martin, C	1
Aeschlimann, JR; Allen, GP; Hershberger, E; Rybak, MJ	1
Coyle, EA; Rybak, MJ	1
Ciabatti, R; Malabarba, A	1
Blanco, MT; Gómez-García, AC; Hurtado, C; Morán, FJ; Pérez-Giraldo, C; Sánchez-Silos, RM	1
Süssmuth, RD	1
Mercier, RC; Rybak, MJ; Stumpo, C	1
Allen, NE; Nicas, TI	1
Courvalin, P; Tulkens, PM; Van Bambeke, F; Van Laethem, Y	1
Carryn, S; Chanteux, H; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Tyteca, D; Van Bambeke, F	1
Van Bambeke, F	1
Loffler, CA; Macdougall, C	1
Baines, SD; Freeman, J; O'Connor, R; Wilcox, MH	1
Baines, SD; Freeman, J; O'Connor, R; Saxton, K; Wilcox, MH	1
Domenech, O; Dufrêne, Y; Francius, G; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F	1
Kim, SJ; Schaefer, J; Singh, M	1
Dietrich, E; Far, AR; Kim, SJ; Parr, TR; Patti, GJ; Schaefer, J; Tanaka, KS; Yu, TY	1
Arhin, FF; Huggler, E; Lew, DP; Moeck, G; Renzoni, A; Vaudaux, P	1
Arhin, FF; Draghi, DC; Moeck, G; Pillar, CM; Sahm, DF	2
Farrell, DJ; Jones, RN; Mendes, RE; Sader, HS; Woosley, LN	1
Becker, K; Denis, O; Garcia, LG; Kahl, BC; Lemaire, S; Proctor, RA; Tulkens, PM; Van Bambeke, F	1
Chilton, CH; Crowther, GS; Fawley, WN; Freeman, J; Lehoux, D; Marquis, M; Moeck, G; Todhunter, SL; Wilcox, MH	1
Canton, R; Janes, R; Knight, D; Macgowan, A; Morrissey, I; Nordmann, P; Seifert, H; Stefani, S	1
Arhin, FF; Belley, A; Deng, H; Moeck, G; Rose, W; Sarmiento, I	1
Arhin, FF; Moeck, G; Sarmiento, I	2
Gerber, Ch; Huber, F; Lang, HP	1
Abell, C; Aeppli, G; Cooper, MA; Kappeler, N; Logan, S; McKendry, RA; Ndieyira, JW	1
Madaj, J; Ślusarz, R; Szulc, M	1
Corey, GR; Giordano, P; Good, S; Gupta, S; Jiang, H; Kabler, H; Lucasti, C; Mehra, P; Moeck, G; O'Riordan, W; Overcash, JS; Perez, A; Porwal, A	1
Chambers, HF	1
Holmes, NE; Howden, BP	1
Morrow, T	1
Bubnova, N; Corey, GR; Good, S; Green, S; Heller, B; Jiang, H; Keech, R; Manos, P; Moeck, G; O'Riordan, W; Singh, R; Wikler, M	1
Adam, HJ; Baxter, MR; Karlowsky, JA; Walkty, AJ; Zhanel, GG	1
Arhin, FF; Jones, RN; Mendes, RE; Moeck, G; Turnidge, JD	1
Corey, GR; Halfpenny, N; Scott, DA; Sulham, K; Thom, H; Thompson, JC	1
Cegelski, L; Romaniuk, JA	1
Arhin, FF; Biedenbach, DJ; Lynch, TF; Moeck, G; Sahm, DF	1
Borgert, SJ; Klinker, KP	1
Fan, W; Lodise, TP; Sulham, KA	1
Raut, A; Rybak, MJ; Smith, JR; Yim, J	1
Arhin, FF; Dudley, MN; Jones, RN; Mendes, RE; Moeck, G; Rhomberg, PR	1
Arhin, F; Belley, A; Lalonde Seguin, D; Moeck, G	1
Concia, E; Falcone, M; Giusti, M; Mazzone, A; Santini, C; Stefani, S; Violi, F	1
Arhin, FF; Belley, A; Moeck, G; Pillar, CM; Shinabarger, DL; Stoneburner, A; Sweeney, D	1
Abell, C; Aeppli, G; Bailey, J; Cooper, MA; McKendry, RA; Ndieyira, JW; Patil, SB; Vögtli, M	1
Kim, SJ; Schaefer, J; Sharif, S; Singh, M	1
Chang, J; Coffman, L; Kim, SJ; Singh, M	1
Arhin, FF; Moeck, G	1
Arhin, FF; Belley, A; Moeck, G; Seguin, DL	1
Arhin, FF; Belley, A; Moeck, G	1
Baker, JR; Bowden, S; Cannon, J; Choi, SK; Francis, E; Joseph, C; Tang, S; Zhou, M	1
Blaskovich, MAT; Cooper, MA; Gong, Y; Kavanagh, A; Ramu, S	1
Adámková, V; Balikova Novotna, G; Borbás, A; Cavanagh, JP; Gazak, R; Herczegh, P; Szűcs, Z; Vimberg, V; Závora, J; Zieglerova, L	1
Chastain, DB; Davis, A	1
Danziger, LH; Harrington, AT; Meyer, K; Wenzler, E; Wu, T	1
Aitken, SL; Dahesh, S; Nizet, V; Sakoulas, G; Tran, TT; Wong, B	1
Chen, XA; Ge, M; Li, YQ; Mo, XT; Qian, H; Wei, W; Zhao, QW	1
Falla, E; Mantopoulos, T; Nathwani, D; Vlachaki, I; Zinzi, D	1
Acquisto, NM; Cheon, E; Sacdal, JPA; Stilwell, AM; Treu, CN	1
Chastain, DB; Cluck, DB; Henao-Martínez, AF; Jackson, BT	1

Reviews

15 review(s) available for vancomycin and oritavancin

Article	Year
Semi-synthetic glycopeptide antibacterials. Bioorganic & medicinal chemistry letters, 2003, Dec-01, Volume: 13, Issue:23 Topics: Animals; Anti-Bacterial Agents; Bacteria; Glycopeptides; Humans	2003
Polypharmacological drug actions of recently FDA approved antibiotics. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Anti-Bacterial Agents; beta-Lactams; Drug Approval; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Humans; Lipoglycopeptides; Pharmaceutical Preparations; Polypharmacology; Quinolones; Small Molecule Libraries; Structure-Activity Relationship; United States; United States Food and Drug Administration	2021
[Glycopeptides]. Annales francaises d'anesthesie et de reanimation, 2000, Volume: 19, Issue:3 Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbon-Oxygen Ligases; Carboxypeptidases; Critical Care; Depression, Chemical; Drug Design; Drug Interactions; Drug Resistance, Microbial; Drug Utilization; Enzyme Inhibitors; Glycopeptides; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Lipoglycopeptides; Membrane Proteins; Operon; Peptide Synthases; Peptidoglycan; Serine-Type D-Ala-D-Ala Carboxypeptidase; Teicoplanin; Transcription Factors; Vancomycin; Vancomycin Resistance	2000
Glycopeptide derivatives. Current medicinal chemistry, 2001, Volume: 8, Issue:14 Topics: Amino Acid Substitution; Animals; Anti-Bacterial Agents; Bacterial Proteins; Binding Sites; Carbon-Oxygen Ligases; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enterococcus; Glycopeptides; Lipoglycopeptides; Structure-Activity Relationship; Teicoplanin; Vancomycin	2001
Vancomycin resistance: small molecule approaches targeting the bacterial cell wall biosynthesis. Chembiochem : a European journal of chemical biology, 2002, Apr-02, Volume: 3, Issue:4 Topics: Anti-Bacterial Agents; Bacterial Proteins; Cell Wall; Glycopeptides; Gram-Positive Bacteria; Lipoglycopeptides; Structure-Activity Relationship; Vancomycin; Vancomycin Resistance	2002
Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS microbiology reviews, 2003, Volume: 26, Issue:5 Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Glycopeptides; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Models, Molecular; Peptidoglycan; Vancomycin; Vancomycin Resistance	2003
Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs, 2004, Volume: 64, Issue:9 Topics: Animals; Anti-Bacterial Agents; Clinical Trials as Topic; Drug Resistance, Bacterial; Glycopeptides; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Structure-Activity Relationship; Teicoplanin; Vancomycin	2004
Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Current opinion in pharmacology, 2004, Volume: 4, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Glycopeptides; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Teicoplanin; Vancomycin	2004
What's new in the treatment of serious MRSA infection? Current opinion in infectious diseases, 2014, Volume: 27, Issue:6 Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Drug Administration Routes; Drug Therapy, Combination; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Severity of Illness Index; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin	2014
Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis. Current medical research and opinion, 2015, Volume: 31, Issue:8 Topics: Acute Disease; Anti-Bacterial Agents; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Skin Diseases, Bacterial; Vancomycin	2015
Bacterial cell wall composition and the influence of antibiotics by cell-wall and whole-cell NMR. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015, Oct-05, Volume: 370, Issue:1679 Topics: Alanine; Anti-Bacterial Agents; Cell Wall; Glycopeptides; Lipoglycopeptides; Lysine; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Peptidoglycan; Staphylococcus aureus; Vancomycin	2015
Beyond Vancomycin: The Tail of the Lipoglycopeptides. Clinical therapeutics, 2015, Dec-01, Volume: 37, Issue:12 Topics: Aminoglycosides; Anti-Bacterial Agents; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Lipopeptides; Methicillin-Resistant Staphylococcus aureus; Teicoplanin; Vancomycin; Vancomycin-Resistant Enterococci	2015
Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Internal and emergency medicine, 2016, Volume: 11, Issue:5 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Daptomycin; Female; Fluoroquinolones; Glycopeptides; Hospitalization; Humans; Iatrogenic Disease; Internal Medicine; Linezolid; Lipoglycopeptides; Male; Minocycline; Oxazolidinones; Skin Diseases, Infectious; Soft Tissue Infections; Teicoplanin; Tigecycline; Vancomycin	2016
Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review. International journal of antimicrobial agents, 2019, Volume: 53, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Osteomyelitis; Retrospective Studies; Skin Diseases, Bacterial; Staphylococcal Infections; Treatment Outcome; Vancomycin	2019
Kimyrsa and Orbactiv - A Tale of Two Formulations. Drug design, development and therapy, 2023, Volume: 17 Topics: Anti-Bacterial Agents; Glycopeptides; Lipoglycopeptides; Vancomycin	2023

Trials

3 trial(s) available for vancomycin and oritavancin

Article	Year
Single-dose oritavancin in the treatment of acute bacterial skin infections. The New England journal of medicine, 2014, Jun-05, Volume: 370, Issue:23 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Double-Blind Method; Drug Administration Schedule; Female; Glycopeptides; Humans; Infusions, Intravenous; Intention to Treat Analysis; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Nausea; Skin Diseases, Bacterial; Vancomycin; Young Adult	2014
One-shot staph treatment offers many advantages. Managed care (Langhorne, Pa.), 2014, Volume: 23, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Drug Approval; Female; Glycopeptides; Humans; Injections, Intravenous; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Staphylococcal Infections; United States; United States Food and Drug Administration; Vancomycin; Young Adult	2014
Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jan-15, Volume: 60, Issue:2 Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Double-Blind Method; Female; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Vancomycin; Young Adult	2015

Other Studies

71 other study(ies) available for vancomycin and oritavancin

Article	Year
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5 Topics: Adsorption; Animals; Anti-Bacterial Agents; Bacterial Infections; Carbon Radioisotopes; Culture Media, Conditioned; Enterococcus; Glycopeptides; Horses; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Polysorbates; Radioligand Assay; Staphylococcus; Streptococcus; Surface Properties; Teicoplanin	2008
Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:2 Topics: Anti-Bacterial Agents; Bacterial Proteins; Colony Count, Microbial; Cryoelectron Microscopy; Enterococcus; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Vancomycin; Vancomycin Resistance	2009
Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Anti-Bacterial Agents; Biofilms; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Glycopeptides; Kinetics; Lipoglycopeptides; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Plankton; Staphylococcus aureus; Vancomycin; Vancomycin Resistance	2009
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4 Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Dose-Response Relationship, Drug; Fusidic Acid; Gentamicins; Humans; Macrophages; Microbial Sensitivity Tests; Oxacillin; Phenotype; Protein Binding; Staphylococcus aureus; Thymidine	2009
Impact of human serum albumin on oritavancin in vitro activity against enterococci. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:6 Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enterococcus; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Protein Binding; Serum Albumin	2009
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:11 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus faecium; Glycopeptides; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus	2009
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19 Topics: Anti-Bacterial Agents; Antiviral Agents; Diazonium Compounds; Doxorubicin; Gram-Positive Bacteria; Microbial Sensitivity Tests; Orthomyxoviridae; Teicoplanin	2009
Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis. Bioorganic & medicinal chemistry letters, 2010, Feb-15, Volume: 20, Issue:4 Topics: Animals; Anti-Bacterial Agents; Bone Density Conservation Agents; Diphosphonates; Glycopeptides; Humans; Lipoglycopeptides; Mice; Microbial Sensitivity Tests; Molecular Structure; Osteomyelitis; Prodrugs; Rats; Staphylococcus aureus; Vancomycin	2010
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12 Topics: Anti-Bacterial Agents; Cell Membrane; Drug Resistance, Bacterial; Enterococcus; Glycopeptides; Lipoglycopeptides; Staphylococcus aureus; Vancomycin	2010
Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1 Topics: Animals; Anti-Bacterial Agents; Cell Line; Drug Resistance, Multiple; Female; Humans; Hydrophobic and Hydrophilic Interactions; Male; Mice; Microbial Sensitivity Tests; Peptidoglycan; Staphylococcus aureus; Structure-Activity Relationship; Sugars; Vancomycin; Vancomycin-Resistant Enterococci	2018
Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. The Journal of antibiotics, 1996, Volume: 49, Issue:6 Topics: Alkylation; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Vancomycin	1996
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:10 Topics: Anti-Bacterial Agents; Enterococcus; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus; Teicoplanin; Vancomycin; Virginiamycin	1996
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:6 Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus faecium; Evaluation Studies as Topic; Gentamicins; Glycopeptides; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Rifampin; Staphylococcus aureus; Vancomycin	1997
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:6 Topics: Anti-Bacterial Agents; Colony Count, Microbial; Drug Resistance, Microbial; Enterococcus faecium; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Time Factors; Vancomycin	1997
The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci. Advances in experimental medicine and biology, 1997, Volume: 418 Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Enterococcus faecalis; Enterococcus faecium; Glycopeptides; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Lipoglycopeptides; Microbial Sensitivity Tests; Teicoplanin; Vancomycin	1997
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:10 Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Glycopeptides; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Teicoplanin; Vancomycin	1997
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms. The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:3 Topics: Ampicillin; Anti-Bacterial Agents; Enterococcus; Enterococcus faecalis; Enterococcus faecium; Gentamicins; Glycopeptides; Gram-Positive Bacteria; Lipoglycopeptides; Microbial Sensitivity Tests; Teicoplanin; Vancomycin	1997
In-vitro susceptibility to LY333328 of vancomycin-resistant enterococci isolated from humans and animals. The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:5 Topics: Animals; Anti-Bacterial Agents; Enterococcus; Feces; Genes, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Vancomycin	1997
Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. The Journal of antimicrobial chemotherapy, 1998, Volume: 41, Issue:2 Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Enterococcus; Glycopeptides; Gram-Positive Bacteria; Kinetics; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus; Teicoplanin; Time Factors; Vancomycin	1998
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:4 Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Endocarditis, Bacterial; Glycopeptides; Kidney; Lipoglycopeptides; Male; Methicillin Resistance; Rabbits; Spleen; Staphylococcal Infections; Vancomycin	1998
Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:10 Topics: Ampicillin; Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus faecium; Glycopeptides; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Vancomycin	1998
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:1 Topics: Animals; Anti-Bacterial Agents; Autoradiography; Bacterial Proteins; Blood Proteins; Carbon-Oxygen Ligases; Culture Media; Drug Resistance, Microbial; Endocarditis, Bacterial; Enterococcus faecalis; Female; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Myocardium; Protein Binding; Rabbits; Vancomycin	1999
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:3 Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Synergism; Enterococcus faecium; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Models, Biological; Time Factors; Vancomycin	1999
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:3 Topics: Ampicillin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Naphthyridines; Rifampin; Staphylococcus aureus; Sulbactam; Teicoplanin; Time Factors; Vancomycin; Virginiamycin	1999
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:11 Topics: Anti-Bacterial Agents; Colony-Forming Units Assay; Drug Therapy, Combination; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Models, Biological; Staphylococcus aureus; Time Factors; Vancomycin; Vancomycin Resistance	2000
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:3 Topics: Anti-Bacterial Agents; Colony Count, Microbial; Glycopeptides; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Models, Biological; Streptococcus pneumoniae; Vancomycin; Vancomycin Resistance	2001
Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin. Chemotherapy, 2001, Volume: 47, Issue:6 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gentamicins; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Incidence; Lipoglycopeptides; Microbial Sensitivity Tests; Naphthyridines; Spain; Streptomycin; Vancomycin	2001
Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. The Journal of antimicrobial chemotherapy, 2002, Volume: 50, Issue:1 Topics: Anti-Bacterial Agents; Colony Count, Microbial; Culture Media; Enterococcus faecium; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Hydrogen-Ion Concentration; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Time Factors; Vancomycin; Vancomycin Resistance	2002
Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:8 Topics: Animals; Anti-Bacterial Agents; Cell Line; Colony Count, Microbial; Glycopeptides; Horseradish Peroxidase; Lipoglycopeptides; Listeria monocytogenes; Lysosomes; Macrophages; Mice; Staphylococcus aureus; Subcellular Fractions; Vancomycin	2004
Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections. Expert review of anti-infective therapy, 2007, Volume: 5, Issue:6 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Clindamycin; Daptomycin; Doxycycline; Folic Acid Antagonists; Global Health; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin; Methicillin Resistance; Minocycline; Oxazolidinones; Prevalence; Staphylococcal Infections; Staphylococcus aureus; Sulfamethoxazole; Teicoplanin; Tigecycline; Trimethoprim; Vancomycin	2007
In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:4 Topics: Anti-Bacterial Agents; Clostridioides difficile; Culture Media; DNA Fingerprinting; Enterocolitis, Pseudomembranous; Genotype; Glycopeptides; Humans; Lipoglycopeptides; Metronidazole; Microbial Sensitivity Tests; Ribotyping; Vancomycin	2008
Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:5 Topics: Anti-Bacterial Agents; Bacterial Toxins; Clindamycin; Clostridioides difficile; Colony Count, Microbial; DNA, Bacterial; Enterocolitis, Pseudomembranous; Glycopeptides; Humans; In Vitro Techniques; Lipoglycopeptides; Microbial Viability; Polymerase Chain Reaction; Ribotyping; Spores, Bacterial; Vancomycin	2008
Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. Biochimica et biophysica acta, 2009, Volume: 1788, Issue:9 Topics: Cardiolipins; Glycopeptides; Lipid Bilayers; Lipoglycopeptides; Membrane Lipids; Microscopy, Atomic Force; Permeability; Phosphatidylethanolamines; Unilamellar Liposomes; Vancomycin	2009
Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus. Journal of molecular biology, 2009, Aug-14, Volume: 391, Issue:2 Topics: Anti-Bacterial Agents; Cell Membrane; Glycopeptides; Lipoglycopeptides; Microscopy, Electron, Transmission; Nitrogen Isotopes; Nuclear Magnetic Resonance, Biomolecular; Protoplasts; Staphylococcus aureus; Vancomycin	2009
Vancomycin and oritavancin have different modes of action in Enterococcus faecium. Journal of molecular biology, 2009, Oct-09, Volume: 392, Issue:5 Topics: Anti-Bacterial Agents; Carbon Isotopes; Cell Wall; Enterococcus faecium; Fluorine; Glycopeptides; Lipoglycopeptides; Magnetic Resonance Spectroscopy; Molecular Structure; Peptidoglycan; Vancomycin	2009
Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital. International journal of antimicrobial agents, 2009, Volume: 34, Issue:6 Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Erythromycin; Glycopeptides; Hospitals, Teaching; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Switzerland; Vancomycin	2009
Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008. International journal of antimicrobial agents, 2010, Volume: 36, Issue:5 Topics: Anti-Bacterial Agents; Europe; Glycopeptides; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Teicoplanin; Vancomycin	2010
Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:3 Topics: Anti-Bacterial Agents; Bacteremia; Enterococcus faecalis; Enterococcus faecium; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Vancomycin; Vancomycin Resistance	2012
Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7 Topics: Anti-Bacterial Agents; Cell Line; Daptomycin; Gentamicins; Glycopeptides; Hemin; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Monocytes; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vitamin K 3	2012
Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci. International journal of antimicrobial agents, 2012, Volume: 40, Issue:6 Topics: Glycopeptides; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus; Vancomycin	2012
Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:12 Topics: Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Toxins; Cecum; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Feces; Glycopeptides; Humans; Lipoglycopeptides; Spores, Bacterial; Vancomycin	2012
Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:1 Topics: Anti-Bacterial Agents; Enterococcus; Europe; Glycopeptides; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus; Streptococcus; Vancomycin; Vancomycin Resistance	2013
Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:1 Topics: Analysis of Variance; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase III as Topic; Colony Count, Microbial; Culture Media; Daptomycin; Drug Dosage Calculations; Glycopeptides; Humans; Infusion Pumps; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Biological; Staphylococcal Infections; Vancomycin	2013
Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA). International journal of antimicrobial agents, 2013, Volume: 41, Issue:4 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Skin Infections; Staphylococcus aureus; Vancomycin	2013
Nanomechanical sensors: Measuring a response in blood. Nature nanotechnology, 2014, Volume: 9, Issue:3 Topics: Anti-Bacterial Agents; Glycopeptides; Humans; Lipoglycopeptides; Nanotechnology; Vancomycin	2014
Surface-stress sensors for rapid and ultrasensitive detection of active free drugs in human serum. Nature nanotechnology, 2014, Volume: 9, Issue:3 Topics: Anti-Bacterial Agents; Bacteria; Biomechanical Phenomena; Biosensing Techniques; Equipment Design; Glycopeptides; Humans; Ligands; Lipoglycopeptides; Models, Biological; Nanotechnology; Solvents; Surface Properties; Vancomycin	2014
Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties. Carbohydrate research, 2014, May-07, Volume: 389 Topics: Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Bacillus subtilis; Carbohydrate Conformation; Glycopeptides; Lipoglycopeptides; Molecular Dynamics Simulation; Peptidoglycan; Staphylococcus aureus; Vancomycin	2014
Pharmacology and the treatment of complicated skin and skin-structure infections. The New England journal of medicine, 2014, Jun-05, Volume: 370, Issue:23 Topics: Anti-Bacterial Agents; Female; Glycopeptides; Humans; Lipoglycopeptides; Male; Skin Diseases, Bacterial; Teicoplanin; Vancomycin	2014
In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. International journal of antimicrobial agents, 2014, Volume: 44, Issue:1 Topics: Acetamides; Anti-Bacterial Agents; Bacterial Proteins; Daptomycin; Gene Expression; Glycopeptides; Linezolid; Lipoglycopeptides; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Oxazolidinones; Vancomycin	2014
In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013. Diagnostic microbiology and infectious disease, 2014, Volume: 80, Issue:4 Topics: Anti-Bacterial Agents; Canada; Drug Resistance, Bacterial; Enterococcus faecalis; Glycopeptides; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Laboratories, Hospital; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Vancomycin	2014
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:4 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Glycopeptides; Gram-Positive Bacteria; Lipoglycopeptides; Microbial Sensitivity Tests; Predictive Value of Tests; Reference Standards; Staphylococcus aureus; Streptococcus; Vancomycin; Vancomycin Resistance	2015
In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014. International journal of antimicrobial agents, 2015, Volume: 46, Issue:6 Topics: Anti-Bacterial Agents; Daptomycin; Drug Resistance, Multiple, Bacterial; Enterococcus; Europe; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Microbial Sensitivity Tests; North America; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus; Streptococcal Infections; Streptococcus; Vancomycin	2015
Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations. Clinical therapeutics, 2016, Jan-01, Volume: 38, Issue:1 Topics: Acute Disease; Ambulatory Care; Anti-Bacterial Agents; Comorbidity; Cost Savings; Decision Trees; Emergency Service, Hospital; Glycopeptides; Hospitalization; Humans; Lipoglycopeptides; Models, Economic; Skin Diseases, Bacterial; Vancomycin	2016
Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4 Topics: Anti-Bacterial Agents; beta-Lactams; Cefazolin; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Ertapenem; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Staphylococcal Infections; Vancomycin; Vancomycin-Resistant Enterococci	2016
Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:5 Topics: Anti-Bacterial Agents; Glycopeptides; Gram-Positive Bacteria; Lipoglycopeptides; Microbial Sensitivity Tests; Vancomycin	2016
Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:7 Topics: Anti-Bacterial Agents; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Teicoplanin; Vancomycin	2016
Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci. The Journal of antimicrobial chemotherapy, 2017, Volume: 72, Issue:2 Topics: Anti-Bacterial Agents; Cross Infection; Enterococcus; Enterococcus faecalis; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Vancomycin; Vancomycin Resistance	2017
Surface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action. Scientific reports, 2017, 02-03, Volume: 7 Topics: Anti-Bacterial Agents; Bacterial Proteins; Biomechanical Phenomena; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Models, Molecular; Protein Binding; Ristocetin; Staphylococcus; Streptococcus; Surface Properties; Vancomycin	2017
Desleucyl-Oritavancin with a Damaged d-Ala-d-Ala Binding Site Inhibits the Transpeptidation Step of Cell-Wall Biosynthesis in Whole Cells of Staphylococcus aureus. Biochemistry, 2017, 03-14, Volume: 56, Issue:10 Topics: Anti-Bacterial Agents; Binding Sites; Cell Wall; Dipeptides; Fluorine; Glycopeptides; Isotopes; Lipoglycopeptides; Peptidoglycan; Peptidyl Transferases; Staphylococcus aureus; Vancomycin	2017
Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis. The journal of physical chemistry. B, 2017, 04-27, Volume: 121, Issue:16 Topics: Alanine; Anti-Bacterial Agents; Biosynthetic Pathways; Cell Wall; Glycopeptides; Humans; Lipoglycopeptides; Staphylococcal Infections; Staphylococcus aureus; Teichoic Acids; Vancomycin	2017
Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci. Journal of global antimicrobial resistance, 2017, Volume: 9 Topics: Anti-Bacterial Agents; Diagnostic Errors; Enterococcus; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus; Vancomycin	2017
In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci. Diagnostic microbiology and infectious disease, 2017, Volume: 89, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Carbon-Oxygen Ligases; Daptomycin; Drug Resistance, Multiple, Bacterial; Enterococcus faecalis; Enterococcus faecium; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Teicoplanin; Vancomycin; Vancomycin Resistance	2017
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:1 Topics: Anti-Bacterial Agents; Daptomycin; Enterococcus faecium; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Vancomycin; Vancomycin Resistance; Vancomycin-Resistant Enterococci	2018
Oritavancin Retains a High Affinity for a Vancomycin-Resistant Cell-Wall Precursor via Its Bivalent Motifs of Interaction. Biochemistry, 2018, 05-08, Volume: 57, Issue:18 Topics: Anti-Bacterial Agents; Cell Wall; Glycopeptides; Gram-Positive Bacteria; Humans; Kinetics; Ligands; Lipoglycopeptides; Molecular Structure; Peptides; Protein Binding; Surface Plasmon Resonance; Vancomycin; Vancomycin Resistance	2018
Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Calcium; Ciprofloxacin; Colistin; Culture Media; Depsipeptides; Escherichia coli; Factor Analysis, Statistical; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxacillin; Penicillin G; Plastics; Polymyxin B; Polysorbates; Rifampin; Teicoplanin; Trimethoprim; Vancomycin	2019
Fluorescence assay to predict activity of the glycopeptide antibiotics. The Journal of antibiotics, 2019, Volume: 72, Issue:2 Topics: Anti-Bacterial Agents; Cell Wall; Enterococcus faecium; Fluorescence; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Peptidoglycan; Protein Binding; Rhodamines; Staining and Labeling; Staphylococcus aureus; Teicoplanin; Vancomycin; Vancomycin-Resistant Enterococci	2019
In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci. The Journal of antimicrobial chemotherapy, 2019, 05-01, Volume: 74, Issue:5 Topics: Anti-Bacterial Agents; Bacteremia; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Enterococcus; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Vancomycin; Vancomycin-Resistant Enterococci	2019
Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Ampicillin; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterococcus faecium; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis; Vancomycin; Vancomycin-Resistant Enterococci	2019
Strategy for Producing the High-Quality Glycopeptide Antibiotic A82846B in ACS synthetic biology, 2021, 11-19, Volume: 10, Issue:11 Topics: Actinomycetales; Amycolatopsis; Anti-Bacterial Agents; CRISPR-Cas Systems; Drug Resistance, Microbial; Glycopeptides; Lipoglycopeptides; Multigene Family; Vancomycin	2021
Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective. The European journal of health economics : HEPAC : health economics in prevention and care, 2022, Volume: 23, Issue:8 Topics: Anti-Bacterial Agents; Daptomycin; Floxacillin; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Quality of Life; State Medicine; Teicoplanin; Vancomycin	2022
Oritavancin versus oral antibiotics for treatment of skin and skin structure infections in the emergency department. The American journal of emergency medicine, 2022, Volume: 60 Topics: Anti-Bacterial Agents; Emergency Service, Hospital; Glycopeptides; Humans; Lipoglycopeptides; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin	2022